Accuracy of Dilution of EUS-FNA Pancreatic Cyst Fluid for Carcinoembryonic

Status Completed

Clinical Trial Summary

The purpose of this research project is to determine if pancreatic cyst fluid can be diluted and provide an accurate Carcinoembryonic Antigen (CEA) level. The investigators hypothesis is that pancreatic cyst fluid obtained by EUS-FNA can be diluted effectively and accurately for the measurement of CEA levels.

Clinical Trial Description

Potential subjects will be identified based on the indication of a pancreatic cyst requiring EUS-FNA. The procedure will be performed as usual per standard protocol with EUS-FNA of the cyst. Once the fluid is aspirated, it will be measured and if the fluid volume is 2.25 mL or greater than the patient will be included in the study.

A micropipette will be used to ensure exact volumes are measured. The first 1 mL of cystic fluid will be sent to the lab for regular CEA analysis, per standard protocol. The remaining fluid, which would usually be discarded, will then be used for the study. The micropipette will be used to mix 0.75 mL of cyst fluid with 0.25 mL of normal saline (designated sample #2). Next, 0.5 mL of cyst fluid will be mixed with 0.5 mL of normal saline for the next study sample (designated sample #3). These two study samples will be sent to the lab separately using de-identified information, and these values will not be part of the patient's medical record and will not affect clinical management or decision-making. The study samples will be given a unique identifier that will not have any patient identification. The unique identifier will allow the study researchers to link the values to the correct patient by using a password protected program that cannot be accessed by the public.

This study will not require any additional patient participation, and will not impact the length of the procedure. The only additional time will be from the study researchers and the EUS technologists diluting the samples, which will not affect the procedure time itself. If a single patient has more than one cyst, each cyst can be included in the study separately. No additional photographs, videos or data other than the standard data for the procedure will be produced. ;

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01494077
Study type	Observational
Source	University of California, Irvine
Contact
Status	Completed
Phase	N/A
Start date	April 2011
Completion date	July 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05572788` - Rectal Indomethacin to Prevent Acute Pancreatitis in EUS-FNA of Pancreatic Cysts	N/A
Not yet recruiting	`NCT06320990` - Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection	Phase 1
Completed	`NCT01770405` - Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract	N/A
Completed	`NCT01643460` - Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts	N/A
Recruiting	`NCT03260842` - Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer
Recruiting	`NCT04291651` - UCSF PANC Cyst Registry
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Recruiting	`NCT03334708` - A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Recruiting	`NCT04140435` - EUS-guided Through-the-needle Microforceps Biopsy Outcomes
Terminated	`NCT00550108` - Management of Incidentally Discovered Pancreatic Cysts	Phase 3
Recruiting	`NCT03492151` - Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
Completed	`NCT03169842` - Cyst Fluid Glucose for On-site Diagnosis of Mucinous Pancreatic Cysts	N/A
Recruiting	`NCT04404101` - Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies	N/A
Recruiting	`NCT06305728` - A Study of Early Cancer Detection in People at High Risk of Developing Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting	`NCT06340620` - EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope	N/A
Recruiting	`NCT02343692` - A Phase II Multicentre Trial of Endoscopic Ultrasound Guided Radiofrequency Ablation of Cystic Tumours of the Pancreas	N/A
Recruiting	`NCT02775461` - Pancreas Registry and High Risk Registry
Active, not recruiting	`NCT01563133` - Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas	N/A
Completed	`NCT00222898` - Cancer Detection in Pancreatic Cysts	N/A
Not yet recruiting	`NCT06276764` - The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Accuracy of Dilution of EUS-FNA Pancreatic Cyst Fluid for Carcinoembryonic Antigen (CEA) Measurement

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms